Results 171 to 180 of about 31,226 (229)

Fluorescence lifetime imaging ophthalmoscopy (FLIO) of patients with neovascular age-related macular degeneration before and after treatment with intravitreal ranibizumab. [PDF]

Graefes Arch Clin Exp Ophthalmol
Sonntag SR, Fries S, Gniesmer S, Grisanti S, Miura Y.   +4 more
europepmc   +1 more source

Flexible Loading Phase Treat-and-Extend Regimen with Faricimab for Neovascular Age-Related Macular Degeneration: A Real-World Study. [PDF]

Biomedicines
Machida A, Kurihara J, Hirata Y, Machida E, Murakami R, Oka A, Yoneda A, Tsuiki E, Oishi A.   +8 more
europepmc   +1 more source

Artificial Intelligence-based characterization of therapeutic response in fluid types and volumes influencing retinal function in neovascular age-related macular degeneration. [PDF]

Sci Rep
Frank-Publig S, Buehl W, Mares V, Fuchs P, Coulibaly LM, Eidenberger A, Scheschy U, Faustmann G, Gumpinger M, Sükei E, Bogunovic H, Reiter GS, Sacu S, Schmidt-Erfurth U.   +13 more
europepmc   +1 more source

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report. [PDF]

Ophthalmol Ther
Kitay AM, Tillmann A, Pfister I, Schild C, Bonanata M, Heck K, Spitznagel T, Gabathuler F, Bartolomeo N, Magnin S, Löliger J, Munk MR, Menghini M, Hatz K, Somfai GM, Zweifel S, Ambresin A, Eandi CM, Feltgen N, Weinberger A, Garweg JG, Kurz-Levin MM.   +21 more
europepmc   +1 more source

Increased aqueous flare after intravitreal brolucizumab injections compared to aflibercept in neovascular age-related macular degeneration. [PDF]

Graefes Arch Clin Exp Ophthalmol
Hashimoto Y, Arai Y, Takahashi H, Tampo H, Kondo R, Takahashi H, Yoshida H, Takahashi R, Inoda S, Kaburaki T, Yanagi Y.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ranibizumab for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine, 2006
Ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--has been evaluated for the treatment of neovascular age-related macular degeneration.In this multicenter, 2-year, double-blind, sham-controlled study, we randomly assigned patients with age-related macular ...
Philip J, Rosenfeld, David M, Brown, Jeffrey S, Heier, David S, Boyer, Peter K, Kaiser, Carol Y, Chung, Robert Y, Kim   +6 more
openaire   +4 more sources

Neovascular Age-Related Macular Degeneration

Ophthalmologica, 2012
<i>Purpose:</i> Neovascular age-related macular degeneration (AMD) is a leading cause of blindness, with an increasing incidence as the elderly population expands. Large, multi-center, randomized, clinical trials have been conducted exploring the safety and efficacy of anti-VEGF treatments. This paper aims to discuss the safety and efficacy
VERITTI, Daniele, SARAO, Valentina, LANZETTA, Paolo   +2 more
openaire   +3 more sources

Neovascular Age-Related Macular Degeneration

Ophthalmology, 2013
Age-related macular degeneration (AMD) progresses through early and intermediate to advanced stages, one of which is neovascular AMD (nAMD). A correct diagnosis of nAMD at an early stage is critical because unlike geographic atrophy, it can be treated with therapeutic agents.
Bianca S. Gerendas, Julia S. Kroisamer, Florian Sulzbacher, Ursula Schmidt-Erfurth   +3 more
openaire   +2 more sources

Neovascular Age-Related Macular Degeneration

2015
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in individuals over the age of 50 years. Choroidal neovascularization (CNV) is the hallmark of 'wet' or 'exudative' AMD, and is responsible for approximately 90% of cases of severe vision loss due to AMD. Vascular endothelial growth factor (VEGF) is a key component in the
Jack, Shao, Maria M, Choudhary, Andrew P, Schachat   +2 more
openaire   +3 more sources